国内药品评审速度过慢是药企普遍反映的问题,其抱怨声也一直存在,尤其是这几年,对此的“控诉”似乎更有超越以往之势。为了解决药品评审过慢的问题,国家食品药品监督管理总局表示会增加国家药审中心的编制,聘任更多的评审人员。同时,也考虑提高药品注册的费用,减少无效、重复的评审。而提高药品注册费的做法似乎已成为共识,也被某些人认为是解决问题的最好途径,甚至在全国两会上,部分代表委员们也疾呼抬高药品评审收费标准。随着提高 The slow speed of domestic drug reviews is a common problem that pharmaceutical companies generally reflect. Whining noise has always been there. Especially in recent years, the “indictment ” seems more out of the past. In order to solve the problem of slow drug review, the State Food and Drug Administration said it will increase the establishment of the national drug review center and appoint more reviewers. At the same time, also consider increasing the cost of drug registration, reduce invalid, repeated review. The practice of raising the drug registration fee seems to have become a consensus. Some people think that it is the best way to solve the problem. Some of the NPC members even scolded the drug review fees even during the NPC and CPPCC sessions. With increasing